Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer
988.8500 -3.25 (-0.33%)
NSE Sep 30, 2025 11:16 AM
Volume: 246.8K
 

988.85
-0.33%
Prabhudas Lilladhar
Zydus Lifesciences (ZYDUSLIF) Q4 EBITDA including other operating income beat our estimates by 8%. We believe gRevlimid + gMirabegron contributes +45% to total FY25E EPS which will see erosion from FY27. Though, company is working on a robust pipeline of complex products, including injectables, 505(b)2, transdermals, NCE, biosimilars and vaccines, they are expected to materialize over the next 23 years. We expect US sales to decline in FY27...
Zydus Lifesciences Ltd. is trading above its 200 day SMA of 949.3
More from Zydus Lifesciences Ltd.
Recommended